Innovative Breakthroughs Unveiled by Agilis Robotics in Endoluminal Surgical Techniques

Monday, February 05, 2024

Agilis Robotics is leading the way in revolutionizing endoluminal surgery through innovative robotic instruments. These instruments, developed by the company, are highly flexible and miniaturized, offering surgeons exceptional dexterity even in challenging anatomies. With Agilis Robotics' technology, surgeons can perform intricate tissue resection procedures directly within natural openings without the need for incisions.

What sets Agilis Robotics' system apart is its seamless integration with standard endoscopes commonly used in hospitals and clinics. This integration not only leverages existing endoscopic expertise but also reduces the learning curve and improves cost-effectiveness. The system's capabilities extend across various endoluminal surgery domains, covering the upper and lower gastrointestinal tract, urinary tract, throat, and gynecology.

Comprising a primary cart, a compact control console, and disposable robotic arms, the system ensures both performance and sterility. Importantly, the cost of Agilis Robotics' system is projected to be significantly lower than conventional robotic systems, making it a more accessible option for medical institutions.

With the global demand for endoluminal surgeries increasing due to rising cancer screenings and early-stage tumor detection, Agilis Robotics is well-positioned to meet this demand. With millions of new GI and bladder cancer cases reported annually worldwide, there is a growing need for effective early-stage treatment options that can reduce procedure times and recurrence rates.

Agilis Robotics is actively working towards regulatory approvals from the Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA), marking significant progress towards commercialization.